enfortumab vedotin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Astellas Pharma's portfolio. Molecular target: Nectin-4.
- Target
- Nectin-4
- Mechanism
- Tubulin inhibitor
pharma · Renal Transplantation · Rheumatoid Arthritis (RA)
Astellas Pharma
Astellas Pharma Inc
Astellas Pharma drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP HQ
12,378 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 0
- Drugs
- 11
- Patents
- 3
Astellas Pharma pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Astellas Pharma drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
enzalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
fezolinetant
Genito-urinary system and sex hormones (G02)US regulatory status: approved. Molecular target: Neuromedin-K receptor.
- Target
- Neuromedin-K receptor
- Mechanism
- Neurokinin 3 receptor antagonist
-
US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
gilteritinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Astellas Pharma's portfolio. Molecular target: Receptor-type tyrosine-protein kinase FLT3.
- Target
- Receptor-type tyrosine-protein kinase FLT3
- Mechanism
- Tyrosine-protein kinase receptor FLT3 inhibitor
-
isavuconazole
Antiinfectives for systemic use (J02)Antiinfectives for systemic use (J02) compound in Astellas Pharma's portfolio.
-
linaclotide
Alimentary tract and metabolism (A06)US regulatory status: approved. Molecular target: Guanylyl cyclase C.
- Target
- Guanylyl cyclase C
- Mechanism
- Heat-stable enterotoxin receptor agonist
-
mirabegron
Genito-urinary system and sex hormones (G04)US regulatory status: approved. Molecular target: Beta-3 adrenergic receptor.
- Target
- Beta-3 adrenergic receptor
- Mechanism
- Beta-3 adrenergic receptor agonist
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to Astellas Pharma in public FDA and regional records. Molecular target: Serotonin 3 (5-HT3) receptor.
- Target
- Serotonin 3 (5-HT3) receptor
- Mechanism
- Serotonin 3 (5-HT3) receptor antagonist
-
tacrolimus
Dermatologicals (D11)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor